TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02484859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
Study: NCT00991068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Description: Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
Study: NCT01680510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alga Dunaliella Bardawil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (starch)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (starch)
Study: NCT02320903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VillageWhere App
Study: NCT00730028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
Study: NCT02513381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3, 3200IU
Description: Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
Study: NCT03502135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl and oxymetazoline HCl nasal spray
Description: Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
Study: NCT04511299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Description: Fish oil-enriched intravenous lipid emulsion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin 20%
Description: MCT/LCT standard intravenous lipid emulsion
Study: NCT04071665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral lumbar interbody fusion
Description: Modified lateral lumbar interbody fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified lateral lumbar interbody fusion
Description: Modified lateral lumbar interbody fusion
Study: NCT02627950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphinhydrochloricum
Description: 5 mg morphine intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphinhydrochloricum
Description: 5 mg morphine intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10 mg MCP intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 180 mg ticagrelor orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg ticagrelor orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg ticagrelor orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic sodium chloride
Description: 10 ml NaCl 0.9% intravenously
Study: NCT04336176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PulseFlow DF boot
Description: Offloading boot

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PulseFlow DF boot
Description: Offloading boot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PulseFlow DF boot
Description: Offloading boot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Usual standard of care (offloading device)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Usual standard of care
Description: Usual standard of care (offloading device)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Usual standard of care (offloading device)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham shoe (closest to barefoot or baseline pressures)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham shoe (closest to barefoot or baseline pressures)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham shoe (closest to barefoot or baseline pressures)
Study: NCT01936337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLX105 Hydrogel
Description: topical administration on psoriatic plaque

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical administration on psoriatic plaque
Study: NCT04132726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy performed by a physiotherapist
Study: NCT04173858

Intervention type: DRUG
Intervention: Naloxegol
Description: 25 mg oral naloxegol once daily.
Study: NCT01103843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loading Dose Arm
Description: Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance Dose Arm
Description: Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
Study: NCT04016415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
Study: NCT01749553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeper Stretch
Description: Posterior shoulder stretch technique
Study: NCT04626154

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Objectively monitoring thoracoabdominal asynchrony
Description: Objectively monitoring thoracoabdominal asynchrony

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Objectively monitoring thoracoabdominal asynchrony
Description: Objectively monitoring thoracoabdominal asynchrony
Study: NCT02188563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Study: NCT02010463

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study: NCT03444792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical dilatation of the cervix
Description: the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~- If failed the surgeon will use artery forceps to dilate cervix
Study: NCT01830335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01619904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy
Description: Peri-operative optimisation of fluid status, based on Oxygen Delivery
Study: NCT00730028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
Study: NCT03902990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Standard treadmill training
Study: NCT04132726

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-effective treatment
Description: non-effective treatment
Study: NCT02837172

Intervention type: OTHER
Intervention: Diffusion Weighted Imaging (DWI)
Description: MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS
Study: NCT03902990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: Standard treadmill training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise programme
Description: Standard exercise programme for Parkinson Disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercise programme
Description: Standard exercise programme for Parkinson Disease

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise programme
Description: Standard exercise programme for Parkinson Disease
Study: NCT04131192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z650
Description: 250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
Study: NCT02234011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02054650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Treatment (OMT)
Description: Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham OMT
Description: Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
Study: NCT01810887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
Study: NCT04131192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
Study: NCT03288831

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will drink a mixture of rice water and Tang flavoring one time.
Study: NCT02195414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVas BCS
Description: The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
Study: NCT05344755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar Sensorial Training
Description: In addition to the routine treatment, plantar sensorial training will be added.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Routine physiotherapy management of the Hallux valgus
Study: NCT04628533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Month Duration Online Behavioral Weight Loss Program
Description: Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Six Month Duration Online Behavioral Weight Loss Program
Description: Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails.
Study: NCT01099709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 10-mg tablet x 1 dose taken with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
Study: NCT02788877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
Study: NCT01810887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
Study: NCT01418755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma injection
Description: The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
Study: NCT03851861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine.
Study: NCT01707147

Intervention type: DRUG
Intervention: Trajenta tablet
Description: Linagliptin
Study: NCT03611140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DP
Description: a package containing a mix of functional foods

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a package containing maltodextrins and caseinate calcium to mimic the DP
Study: NCT00003565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01382069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone Undecanoate
Description: Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with capsules that look like the DMAU capsules but with no active ingredients
Study: NCT00060892

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HGF plasmid
Description: Intramuscular injections into index leg on Days 0, 14, and 28

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HGF plasmid
Description: Intramuscular injections into index leg on Days 0, 14, and 28

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HGF plasmid
Description: Intramuscular injections into index leg on Days 0, 14, and 28

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: HGF plasmid
Description: Intramuscular injections into index leg on Days 0, 14, and 28
Study: NCT00775372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250mg/5mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 250mg/5mL
Study: NCT03854487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham mirror
Description: A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.